Mandatory Rest Period

Too bad. A potential PPMS drug Rituxan did not come through when the trial data was compiled.

"A late-stage clinical trial of oncology drug Rituxan failed to show it was effective in treating a certain type of multiple sclerosis, according to Genentech Inc. and Biogen Idec Inc. and Biogen said that in a Phase II/III trial, Rituxan didn't show the antibody-based medication could effectively slow the progression of primary-progressive multiple sclerosis, or PPMS.

The companies added that currently there are no effective treatments for PPMS, a particularly hard to treat form of the disease. Rituxan is already approved for the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis."

- posted by Anonymous @ 11:05 AM - Link @ 11:05 AM - Link to this post - Comments (0)

			Hi, I’m Kim! This site provides a little insight to my journey of being diagnosised with Remitting Relapsing Multiple Sclerosis on October 26th 2004. I review books and documentaries, post MS-related news, and share my photos. Subscribe (RSS) My bloglines Archives Current November 2004 December 2004 January 2005 February 2005 March 2005 April 2005 May 2005 June 2005 July 2005 August 2005 September 2005 October 2005 November 2005 December 2005 January 2006 February 2006 March 2006 April 2006 May 2006 June 2006 July 2006 August 2006 September 2006 October 2006 November 2006 December 2006 January 2007 February 2007 March 2007 April 2007 May 2007 June 2007 July 2007 August 2007 September 2007 October 2007 November 2007 December 2007 January 2008 February 2008 March 2008 April 2008 May 2008 June 2008 July 2008 August 2008 September 2008 October 2008 November 2008 December 2008 January 2009 February 2009 March 2009 April 2009 May 2009 June 2009 July 2009 August 2009 September 2009 October 2009 November 2009 December 2009 January 2010 February 2010 March 2010 May 2010 June 2010 July 2010 September 2010 November 2011

	Tuesday, April 15, 2008 *Rituxan didn't slow PPMS in trials :(* Too bad. A potential PPMS drug Rituxan did not come through when the trial data was compiled. "A late-stage clinical trial of oncology drug Rituxan failed to show it was effective in treating a certain type of multiple sclerosis, according to Genentech Inc. and Biogen Idec Inc. and Biogen said that in a Phase II/III trial, Rituxan didn't show the antibody-based medication could effectively slow the progression of primary-progressive multiple sclerosis, or PPMS. The companies added that currently there are no effective treatments for PPMS, a particularly hard to treat form of the disease. Rituxan is already approved for the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis." - posted by Anonymous @ 11:05 AM - Link @ 11:05 AM - Link to this post - Comments (0)